Glenmark Pharmaceuticals receives approval for 'Salmecort' in Russia

12 Mar 2015 Evaluate

Glenmark Pharmaceuticals, the research-led global integrated pharmaceutical company, has received approval for Salmecort (Salmeterol+Fluticasone) MDI inhaler, from the Ministry of Health (MoH), Russia. The combination preparation contains salmeterol xinafoate and fluticasone propionate, used in the management of asthma and chronic obstructive pulmonary disease (COPD). The approval is for 25mcg+50mcg/dose, 25 mcg + 125 mcg/dose and 25 meg + 250 mcg/dose formulation strengths. Salmecort is expected to be available in the Russian market in Q2 FY 2015-16.

The approval marks Glenmark’s entry into the respiratory inhaler market in Russia. According to IMS, the total inhaler market in Russia is estimated to be around $283 million, out of which the total MDI market is valued at around $107 million.

Glenmark’s current portfolio consists of 95 products authorized for distribution in the US marketplace and 74 ANDA’s pending approval with the USFDA. In addition to these internal filings, GGI continues to identify and explore external development partnerships to supplement and accelerate the growth of the existing pipeline and portfolio.

Glenmark Pharma Share Price

1965.75 -8.40 (-0.43%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×